Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders

Adel Al-Naqdy, Ibrahim Kutty, Saada Al-Harthi, Mohammed Al-Buloshi, Masoud Al-Maskari

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: High titers of antibodies to thyroglobulin (ATA) and thyroid microsomal antigen (ATMA) are the hallmarks of human autoimmune thyroid diseases. The clinical significance of these autoantibodies in other thyroid disorders is still unclear. The aim of this study was to analyze the prevalence and titres of these antibodies in Omani patients (mean age 32, range 5-81 years) with different thyroid disorders. This was done in order to investigate any correlation regarding clinical manifestations that may be unique to patients attending Sultan Qaboos University Hospital (SQUH). Method: Serum levels of ATA and ATMA in 400 cases involving four groups of thyroid disorders (one hundred each with Hashimoto's disease, Graves' disease, thyroid cancer and goitre) and 100 cases of non-thyroid disorders were studied. The antibodies were tested using a commercial haemagglutination assay (Thymune-T and Thymune-M). Results: The overall prevalence of ATA or ATMA antibodies with thyroid disease was 47% and in non-thyroid disorders was 8%. The ATA was positive in 27% of all the patients with thyroid disorders compared to only 4% of those in the non-thyroid groups while ATMA was positive in 42% and 8% respectively. Among all patients, ATA and ATMA were positive in 64% of patients with Graves's disease, 81% in those with Hashimoto's, 30% of goiter patients, and 20% of those with thyroid carcinoma. The prevalence according to the age within each group for the three ranges: less than 20 years, between 20-40 years and over 40 years, showed the following results: within Graves were 12, 49 and 39% respectively; in the goitre group: 23, 55 and 22%; in the Hashimotos' group: 18, 54 and 28% and 7, 56 and 37% among the patients with thyroid carcinoma. The female to male ratio prevalence was 68% and 32% in Graves disease, 92% and 8% in Hashimotos', 75% and 25% in thyroid cancer and 88% and 12% in goiter. Conclusions: This study confirms the prevalence of a high level of thyroid autoantibodies in these Omani patients as in Caucasians, and its correlation to age and gender. It also indicated the importance of screening for ATA and ATMA in non-autoimmune thyroid disorders. Their significance in thyroid cancers needs further elucidation.

Original languageEnglish
Pages (from-to)111-114
Number of pages4
JournalBahrain Medical Bulletin
Volume25
Issue number3
Publication statusPublished - Sep 2003

Fingerprint

Thyroid Gland
Thyroid Neoplasms
Goiter
Graves Disease
Antigens
Thyroid Diseases
Autoantibodies
Antibodies
thyroid microsomal antibodies
anti-thyroglobulin
Hashimoto Disease
Thyroglobulin
Hemagglutination
Autoimmune Diseases
Cross-Sectional Studies
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Al-Naqdy, A., Kutty, I., Al-Harthi, S., Al-Buloshi, M., & Al-Maskari, M. (2003). Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders. Bahrain Medical Bulletin, 25(3), 111-114.

Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders. / Al-Naqdy, Adel; Kutty, Ibrahim; Al-Harthi, Saada; Al-Buloshi, Mohammed; Al-Maskari, Masoud.

In: Bahrain Medical Bulletin, Vol. 25, No. 3, 09.2003, p. 111-114.

Research output: Contribution to journalArticle

Al-Naqdy, A, Kutty, I, Al-Harthi, S, Al-Buloshi, M & Al-Maskari, M 2003, 'Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders', Bahrain Medical Bulletin, vol. 25, no. 3, pp. 111-114.
Al-Naqdy, Adel ; Kutty, Ibrahim ; Al-Harthi, Saada ; Al-Buloshi, Mohammed ; Al-Maskari, Masoud. / Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders. In: Bahrain Medical Bulletin. 2003 ; Vol. 25, No. 3. pp. 111-114.
@article{5c781d461e7d4e4c896a432bbd766c71,
title = "Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders",
abstract = "Objective: High titers of antibodies to thyroglobulin (ATA) and thyroid microsomal antigen (ATMA) are the hallmarks of human autoimmune thyroid diseases. The clinical significance of these autoantibodies in other thyroid disorders is still unclear. The aim of this study was to analyze the prevalence and titres of these antibodies in Omani patients (mean age 32, range 5-81 years) with different thyroid disorders. This was done in order to investigate any correlation regarding clinical manifestations that may be unique to patients attending Sultan Qaboos University Hospital (SQUH). Method: Serum levels of ATA and ATMA in 400 cases involving four groups of thyroid disorders (one hundred each with Hashimoto's disease, Graves' disease, thyroid cancer and goitre) and 100 cases of non-thyroid disorders were studied. The antibodies were tested using a commercial haemagglutination assay (Thymune-T and Thymune-M). Results: The overall prevalence of ATA or ATMA antibodies with thyroid disease was 47{\%} and in non-thyroid disorders was 8{\%}. The ATA was positive in 27{\%} of all the patients with thyroid disorders compared to only 4{\%} of those in the non-thyroid groups while ATMA was positive in 42{\%} and 8{\%} respectively. Among all patients, ATA and ATMA were positive in 64{\%} of patients with Graves's disease, 81{\%} in those with Hashimoto's, 30{\%} of goiter patients, and 20{\%} of those with thyroid carcinoma. The prevalence according to the age within each group for the three ranges: less than 20 years, between 20-40 years and over 40 years, showed the following results: within Graves were 12, 49 and 39{\%} respectively; in the goitre group: 23, 55 and 22{\%}; in the Hashimotos' group: 18, 54 and 28{\%} and 7, 56 and 37{\%} among the patients with thyroid carcinoma. The female to male ratio prevalence was 68{\%} and 32{\%} in Graves disease, 92{\%} and 8{\%} in Hashimotos', 75{\%} and 25{\%} in thyroid cancer and 88{\%} and 12{\%} in goiter. Conclusions: This study confirms the prevalence of a high level of thyroid autoantibodies in these Omani patients as in Caucasians, and its correlation to age and gender. It also indicated the importance of screening for ATA and ATMA in non-autoimmune thyroid disorders. Their significance in thyroid cancers needs further elucidation.",
author = "Adel Al-Naqdy and Ibrahim Kutty and Saada Al-Harthi and Mohammed Al-Buloshi and Masoud Al-Maskari",
year = "2003",
month = "9",
language = "English",
volume = "25",
pages = "111--114",
journal = "Bahrain Medical Bulletin",
issn = "1012-8298",
publisher = "Bahrain Medical Bulletin",
number = "3",

}

TY - JOUR

T1 - Anti-thyroglobulin and anti-thyroid microsomal antibodies in thyroid disorders

AU - Al-Naqdy, Adel

AU - Kutty, Ibrahim

AU - Al-Harthi, Saada

AU - Al-Buloshi, Mohammed

AU - Al-Maskari, Masoud

PY - 2003/9

Y1 - 2003/9

N2 - Objective: High titers of antibodies to thyroglobulin (ATA) and thyroid microsomal antigen (ATMA) are the hallmarks of human autoimmune thyroid diseases. The clinical significance of these autoantibodies in other thyroid disorders is still unclear. The aim of this study was to analyze the prevalence and titres of these antibodies in Omani patients (mean age 32, range 5-81 years) with different thyroid disorders. This was done in order to investigate any correlation regarding clinical manifestations that may be unique to patients attending Sultan Qaboos University Hospital (SQUH). Method: Serum levels of ATA and ATMA in 400 cases involving four groups of thyroid disorders (one hundred each with Hashimoto's disease, Graves' disease, thyroid cancer and goitre) and 100 cases of non-thyroid disorders were studied. The antibodies were tested using a commercial haemagglutination assay (Thymune-T and Thymune-M). Results: The overall prevalence of ATA or ATMA antibodies with thyroid disease was 47% and in non-thyroid disorders was 8%. The ATA was positive in 27% of all the patients with thyroid disorders compared to only 4% of those in the non-thyroid groups while ATMA was positive in 42% and 8% respectively. Among all patients, ATA and ATMA were positive in 64% of patients with Graves's disease, 81% in those with Hashimoto's, 30% of goiter patients, and 20% of those with thyroid carcinoma. The prevalence according to the age within each group for the three ranges: less than 20 years, between 20-40 years and over 40 years, showed the following results: within Graves were 12, 49 and 39% respectively; in the goitre group: 23, 55 and 22%; in the Hashimotos' group: 18, 54 and 28% and 7, 56 and 37% among the patients with thyroid carcinoma. The female to male ratio prevalence was 68% and 32% in Graves disease, 92% and 8% in Hashimotos', 75% and 25% in thyroid cancer and 88% and 12% in goiter. Conclusions: This study confirms the prevalence of a high level of thyroid autoantibodies in these Omani patients as in Caucasians, and its correlation to age and gender. It also indicated the importance of screening for ATA and ATMA in non-autoimmune thyroid disorders. Their significance in thyroid cancers needs further elucidation.

AB - Objective: High titers of antibodies to thyroglobulin (ATA) and thyroid microsomal antigen (ATMA) are the hallmarks of human autoimmune thyroid diseases. The clinical significance of these autoantibodies in other thyroid disorders is still unclear. The aim of this study was to analyze the prevalence and titres of these antibodies in Omani patients (mean age 32, range 5-81 years) with different thyroid disorders. This was done in order to investigate any correlation regarding clinical manifestations that may be unique to patients attending Sultan Qaboos University Hospital (SQUH). Method: Serum levels of ATA and ATMA in 400 cases involving four groups of thyroid disorders (one hundred each with Hashimoto's disease, Graves' disease, thyroid cancer and goitre) and 100 cases of non-thyroid disorders were studied. The antibodies were tested using a commercial haemagglutination assay (Thymune-T and Thymune-M). Results: The overall prevalence of ATA or ATMA antibodies with thyroid disease was 47% and in non-thyroid disorders was 8%. The ATA was positive in 27% of all the patients with thyroid disorders compared to only 4% of those in the non-thyroid groups while ATMA was positive in 42% and 8% respectively. Among all patients, ATA and ATMA were positive in 64% of patients with Graves's disease, 81% in those with Hashimoto's, 30% of goiter patients, and 20% of those with thyroid carcinoma. The prevalence according to the age within each group for the three ranges: less than 20 years, between 20-40 years and over 40 years, showed the following results: within Graves were 12, 49 and 39% respectively; in the goitre group: 23, 55 and 22%; in the Hashimotos' group: 18, 54 and 28% and 7, 56 and 37% among the patients with thyroid carcinoma. The female to male ratio prevalence was 68% and 32% in Graves disease, 92% and 8% in Hashimotos', 75% and 25% in thyroid cancer and 88% and 12% in goiter. Conclusions: This study confirms the prevalence of a high level of thyroid autoantibodies in these Omani patients as in Caucasians, and its correlation to age and gender. It also indicated the importance of screening for ATA and ATMA in non-autoimmune thyroid disorders. Their significance in thyroid cancers needs further elucidation.

UR - http://www.scopus.com/inward/record.url?scp=0041320742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041320742&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 111

EP - 114

JO - Bahrain Medical Bulletin

JF - Bahrain Medical Bulletin

SN - 1012-8298

IS - 3

ER -